AFM28 has been designed to bring a new immunotherapeutic approach for CD123-positive myeloid malignancies patients, including MDS and AML. Credit: Animalculist /

Affimed has dosed the first participant in the first-in-human Phase I trial of AFM28 to treat CD123-positive relapsed/refractory (r/r) acute myeloid leukaemia (AML) patients.

The open label, multicentre, dose escalation Phase I AFM28-101 trial has been designed for evaluating pharmacodynamics, pharmacokinetics, tolerability, and safety of AFM28 monotherapy in the indicated patients.

The dose escalation’s aim is to establish the maximum tolerated dose (MTD) and/or one or more recommended Phase II doses (RP2D).

Affimed also plans to develop AFM28 along with allogeneic natural killer (NK) cell therapy.

The tetravalent bispecific CD123- and CD16A-binding innate cell engager (ICE) AFM28 has been developed on the Redirected Optimized Cell Killing (ROCK) platform of Affimed.

AFM28 works by engaging NK cells for commencing tumour cell killing through antibody-dependent cellular cytotoxicity (ADCC).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It has been designed to bring a new immunotherapeutic approach for CD123-positive myeloid malignancies patients, including myelodysplastic syndrome (MDS) and AML.

Affimed CEO Dr Adi Hoess said: “I’m proud of this milestone as AFM28 represents Affimed’s third wholly owned ICE molecule to enter the clinic.

“AFM28 has been designed to improve outcomes for AML patients in a differentiated manner from drugs currently used or in development for the treatment of AML.

“AFM28 broadens our footprint in haematological malignancies in addition to AFM13’s encouraging clinical activity as a single agent and in combination with NK cells and adds to our clinically validated pipeline with multiple expected data readouts in 2023.”

Last December, the French National Agency for the Safety of Medicines and Health Products (ANSM) authorised Affimed’s clinical trial application (CTA) for the Phase I study of AFM28 (AFM28-101) monotherapy for relapsed/refractory (r/r) AML.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.